Hahn Capital Management LLC lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.4% during the first quarter, Holdings Channel reports. The firm owned 241,184 shares of the medical instruments supplier’s stock after selling 5,864 shares during the period. Becton, Dickinson and makes up approximately 4.2% of Hahn Capital Management LLC’s portfolio, making the stock its 4th largest position. Hahn Capital Management LLC’s holdings in Becton, Dickinson and were worth $44,243,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Rockland Trust Co. purchased a new position in shares of Becton, Dickinson and during the first quarter valued at approximately $307,000. Wells Fargo & Company MN raised its position in Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock valued at $602,246,000 after buying an additional 39,362 shares during the last quarter. AMG National Trust Bank raised its position in Becton, Dickinson and by 4.2% in the first quarter. AMG National Trust Bank now owns 9,880 shares of the medical instruments supplier’s stock valued at $1,813,000 after buying an additional 401 shares during the last quarter. Integrated Wealth Management raised its position in Becton, Dickinson and by 3.4% in the first quarter. Integrated Wealth Management now owns 5,444 shares of the medical instruments supplier’s stock valued at $999,000 after buying an additional 181 shares during the last quarter. Finally, Nationwide Fund Advisors raised its position in Becton, Dickinson and by 64.2% in the first quarter. Nationwide Fund Advisors now owns 96,582 shares of the medical instruments supplier’s stock valued at $17,717,000 after buying an additional 37,752 shares during the last quarter. Hedge funds and other institutional investors own 75.57% of the company’s stock.

Becton, Dickinson and Company (NYSE:BDX) traded up 0.42% during midday trading on Monday, reaching $201.21. The company’s stock had a trading volume of 218,749 shares. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The firm has a market cap of $45.79 billion, a price-to-earnings ratio of 58.27 and a beta of 1.05. The company’s 50-day moving average is $198.90 and its 200 day moving average is $187.70.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company’s quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.35 earnings per share. Equities analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.46%. Becton, Dickinson and’s dividend payout ratio is 83.43%.

TRADEMARK VIOLATION NOTICE: “Becton, Dickinson and Company (NYSE:BDX) Position Decreased by Hahn Capital Management LLC” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/becton-dickinson-and-company-nysebdx-position-decreased-by-hahn-capital-management-llc/1487009.html.

Several equities analysts recently issued reports on the company. Barclays PLC restated an “equal weight” rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Zacks Investment Research lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. BidaskClub lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Sunday, August 6th. Finally, Bank of America Corporation restated a “buy” rating and set a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Becton, Dickinson and currently has an average rating of “Buy” and an average price target of $195.79.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the transaction, the insider now directly owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,019 shares of company stock worth $8,368,433. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.